Is reserpine a human teratogen?
A single stillborn female with craniofacial, abdominal, and central nervous system malformations was exposed to reserpine during the first six weeks of gestation. Parallels between the malformations present in this infant and those induced in rats through exposure to reserpine at analogous periods of gestation suggest that reserpine may pose specific risks for malformations in some pregnancies.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000015:Abnormalities, Multiple / Q000139:chemically induced*; D000328:Adult; D002490:Central Nervous System / Q000002:abnormalities; D005147:Facial Bones / Q000002:abnormalities; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D012110:Reserpine / Q000009:adverse effects* / Q000627:therapeutic use; D012306:Risk; D012886:Skull / Q000002:abnormalities
D012110:Reserpine